

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
 - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
 - FADED TEXT
 - ILLEGIBLE TEXT
 - SKEWED/SLANTED IMAGES
 - COLORED PHOTOS
 - BLACK OR VERY BLACK AND WHITE DARK PHOTOS
 - GRAY SCALE DOCUMENTS
-

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/70, C12N 15/11 C07K 15/00, C07H 21/00 G01N 33/576	A1	(11) International Publication Number: WO 94/05813 (43) International Publication Date: 17 March 1994 (17.03.94)
(21) International Application Number: PCT/JP93/01293 (22) International Filing Date: 10 September 1993 (10.09.93) (30) Priority data: 945,289 10 September 1992 (10.09.92) US 5/87195 14 April 1993 (14.04.93) JP (60) Parent Applications or Grants (63) Related by Continuation US 945,289 (CIP) Filed on 10 September 1993 (10.09.93) US 5/87195 (CIP) Filed on 14 April 1993 (14.04.93) (71) Applicant (for all designated States except JP US): MOCHIDA PHARMACEUTICAL CO., LTD. [JP/JP]; 7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 160 (JP). (71) Applicants (for all designated States except US): JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE [JP/JP]; 668, Okubo, Shimizu-machi, Kumamoto-shi, Kumamoto 860 (JP). ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ANDERSON, Kevin, P. [US/US]; 2772 La Gran Via, Carlsbad, CA 92009 (US). HANECAK, Ronnie, C. [US/US]; 904 Calle Ve-		nezia, San Clemente, CA 92672 (US). HOSHIKO, Kazuya [JP/JP]; A-102, 1909-47, Tateyama, Kikutomi, Koshi-machi, Kikuchi-gun, Kumamoto 861-11 (JP). NOZAKI, Chikateru [JP/JP]; 1-444, Musashigaoka, Kumamoto-shi, Kumamoto 862 (JP). NISHIHARA, Tsukasa [JP/JP]; 1749-6, Kamitatsuda, Tatsuda-machi, Kumamoto-shi, Kumamoto 862 (JP). NAKATAKE, Hiroshi [JP/JP]; 2333-15, Tsukure, Kikuyo-machi, Kikuchi-gun, Kumamoto 869-11 (JP). HAMADA, Fukusaburo [JP/JP]; 2679-2, Suya, Nishigoshi-machi, Kikuchi-gun, Kumamoto 861-11 (JP). ETO, Tatsuo [JP/US]; 158 Via Morella, Encinitas, CA 92024 (US). FURUKAWA, Shinichi [JP/JP]; 2012-28, Toyooka, Koshi-machi, Kikuchi-gun, Kumamoto 861-11 (JP). (74) Agents: AOYAMA, Tamotsu et al.; Twin 21 Mid Tower, 1-61, Shiromi 2-chome, Chuo-ku, Osaka-shi, Osaka 540 (JP). (81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES		
(57) Abstract		
<p>Antisense oligonucleotides are provided which are complementary to at least a portion of HCV RNA and specifically hybridizable therewith. These oligonucleotides can be administered to inhibit the replication of Hepatitis C virus <i>in vivo</i> or <i>in vitro</i> and to treat Hepatitis C virus-associated disease. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	CN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

- 1 -

DESCRIPTION

COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES

FIELD OF THE INVENTION

This invention relates to the design and synthesis of
5 antisense oligonucleotides which can be administered to inhibit
the replication of Hepatitis C virus *in vivo* or *in vitro* and to
treat Hepatitis C virus-associated disease. These compounds can
be used either prophylactically or therapeutically to reduce
the severity of diseases associated with Hepatitis C virus.
10 Oligonucleotides which are specifically hybridizable with RNA
targets are disclosed.

BACKGROUND OF THE INVENTION

The predominant form of hepatitis currently resulting
from transfusions is not related to the previously
15 characterized Hepatitis A virus or Hepatitis B virus and has
been referred to as Non-A, Non-B Hepatitis (NANBH). NANBH
currently accounts for over 90% of cases of post-transfusion
hepatitis. Estimates of the frequency of NANBH in transfusion
recipients range from 5%-13% for those receiving volunteer
20 blood, or 25-54% for those receiving blood from commercial
sources.

Acute NANBH, while often less severe than acute
disease caused by Hepatitis A or Hepatitis B viruses,
occasionally leads to severe or fulminant hepatitis. Of greater
25 concern, progression to chronic hepatitis is much more common
after NANBH than after either Hepatitis A or Hepatitis B
infection. Chronic NANBH has been reported in 10%-70% of

- 2 -

infected individuals. This form of hepatitis can be transmitted even by asymptomatic patients, and frequently progresses to malignant disease such as cirrhosis and hepatocellular carcinoma. Chronic active hepatitis, with or without cirrhosis, is seen in 44%-90% of posttransfusion hepatitis cases. Of those patients who developed cirrhosis, approximately one-fourth died of liver failure.

Chronic active NANBH is a significant problem to hemophiliacs who are dependent on blood products; 5%-11% of hemophiliacs die of chronic end-stage liver disease. Cases of NANBH other than those traceable to blood or blood products are frequently associated with hospital exposure, accidental needle stick, or tattooing. Transmission through close personal contact also occurs, though this is less common for NANBH than for Hepatitis B.

The causative agent of the majority of NANBH has recently been identified and is now referred to as Hepatitis C Virus (HCV). Houghton et al., EP Publication 318,216; Choo et al., *Science* 1989, 244, 359-362. Based on serological studies using recombinant DNA-generated antigens it is now clear that HCV is the causative agent of most cases of post-transfusion NANBH. Clones of cDNA prepared from nucleic acid isolated from concentrated virus particles were originally isolated based on their ability to encode polypeptides which reacted with sera from NANBH patients. These clones hybridized with RNA, but not DNA, isolated from infected liver tissue, indicating the presence of an RNA genome. Hybridization analyses and sequencing of the cDNA clones revealed that RNA present in infected liver and particles was the same polarity as that of the coding strand of the cDNAs; in other words, the virus genome is a positive or plus-strand RNA genome. EP Publication 318,216 (Houghton et al.) disclose partial genomic sequences of HCV-1, and teach recombinant DNA methods of cloning and expressing HCV sequences and HCV polypeptides, techniques of HCV immunodiagnosics, HCV probe diagnostic techniques, anti-HCV antibodies, and methods of isolating new HCV sequences. Houghton et al. also disclose additional HCV sequences and

- 3 -

teach application of these sequences and polypeptides in immunodiagnostics, probe diagnostics, anti-HCV antibody production, PCR technology and recombinant DNA technology. The concept of using antisense polynucleotides as inhibitors of viral replication is disclosed, but no specific targets are taught. Oligomer probes and primers based on the sequences disclosed are also provided. EP Publication 419,182 (Miyamura et al.) discloses new HCV isolates J1 and J7 and use of sequences distinct from HCV-1 sequences for screens and diagnostics.

The only treatment regimen shown to be effective for the treatment of chronic NANBH is interferon- α . Most NANBH patients show an improvement of clinical symptoms during interferon treatment, but relapse is observed in at least half of patients when treatment is interrupted. Significant improvements in antiviral therapy are therefore greatly desired.

OBJECTS OF THE INVENTION

It is an object of this invention to provide oligonucleotides which are capable of hybridizing with RNA of HCV to inhibit the synthesis or function of said RNA.

It is another object of this invention to provide oligonucleotides which are capable of hybridizing with RNA of HCV to inhibit replication of the virus.

It is a further object to provide oligonucleotides which can modulate the expression of HCV through antisense interaction with viral RNA.

Yet another object of this invention is to provide methods of prophylaxis, diagnostics and therapeutics for acute or chronic HCV infection.

A further object of this invention is to provide methods of prophylaxis, diagnostics and therapeutics for HCV-associated diseases.

Methods, materials and kits for detecting the presence or absence of HCV or HCV RNA in a sample suspected of containing it are further objects of the invention.

- 4 -

These and other objects will become apparent to persons of ordinary skill in the art from a review of the instant specification and appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 is the sequence of nucleotides 1-686 comprising the entire 5'-untranslated region (nucleotides 1-341) and a 145-nucleotide core region sequence.

 Figure 2 is a bar graph showing inhibition of HCV core protein translation by antisense oligonucleotides complementary
10 to the region from nucleotide 1 to 350 of HCV RNA.

 Figure 3 is a bar graph showing inhibition of HCV core protein translation by 2'-O-methylated antisense oligonucleotides and selected unmodified oligonucleotides of the same sequence.

15 Figure 4 is an autoradiograph showing inhibitory activities of oligonucleotides IA-80, IA-110, IA-140, IA-260, IA-300 and IA-360 against HCV core protein translation in vitro.

 Figure 5 is a bar graph showing inhibition of HCV core
20 protein translation in the modified in vitro translation assay by oligonucleotides complementary to the region from nucleotide 1 to 371 of HCV RNA.

 Figure 6 is a bar graph showing inhibition of HCV translation by 2'-O-methyl/P=O antisense oligonucleotides
25 around the loop C region and AUG codon/core protein coding region.

 Figure 7 is a line graph showing dose-dependent inhibition of HCV core protein translation by P=O, P=S, P=O/2'-O-Me and P=S/2'-O-Me versions of IA-340.

30 Figure 8 is a bar graph showing results of a screen of phosphorothioate oligonucleotides by in vitro translation assay after treatment with RNase H.

 Figure 9 is a bar graph showing inhibitory activities of 2'-O-propyl and 2'-O-methyl oligonucleotides.

- 5 -

SUMMARY OF THE INVENTION

In accordance with the present invention, compositions and methods for modulating the effects of HCV infection are provided. Oligonucleotides complementary to, and specifically
5 hybridizable with, selected sequences of HCV RNA are provided. The HCV 5' end hairpin loop, 5' end 6-base-pair repeats, 5' end untranslated region, polyprotein translation initiation codon, core protein coding region, ORF 3 translation initiation codon, 3'-untranslated region, 3' end palindrome region, R2 sequence
10 and 3' end hairpin loop are preferred targets. Methods for diagnosing or treating disease states by administering oligonucleotides, either alone or in combination with a pharmaceutically acceptable carrier, to animals suspected of having HCV-associated diseases are also provided.

15 The relationship between the target RNA and oligonucleotides complementary to at least a portion of the target, and specifically hybridizable with it, is commonly denoted as "antisense". The oligonucleotides are able to inhibit the function of viral RNA by interfering with its
20 replication, transcription into mRNA, translation into protein, packaging into viral particles or any other activity necessary to its overall biological function. The failure of the RNA to perform all or part of its function results in failure of all or a portion of the normal life cycle of the virus.

25 It has been found that antisense oligonucleotides designed to target viruses can be effective in diminishing viral infection. It is preferred that oligonucleotides have between about 5 and about 50 nucleotide units. It is also preferred that the oligonucleotides be specifically
30 hybridizable with the HCV 5' end hairpin loop, 5' end 6-base-pair repeats, 5' end untranslated region, polyprotein translation initiation codon, core protein coding region, ORF 3 translation initiation codon, 3'-untranslated region, 3' end palindrome region, R2 sequence or 3' end hairpin loop. The
35 oligonucleotide may be modified to increase nuclease resistance and to increase its efficacy.

In accordance with preferred embodiments, the viral

- 6 -

RNA is interfered with to an extent sufficient to inhibit HCV infection and/or HCV replication. Thus, oligonucleotides which are capable of interacting with portions of HCV RNA are comprehended. Animals suspected of having HCV-associated
5 disease are contacted with an oligonucleotide made in accordance with this invention. In particular, the present invention is believed to be effective in the treatment of acute and chronic HCV infections and HCV-associated disease, either prophylactically or therapeutically.

10 It is to be expected that differences in the RNA of HCV from different strains and from different types within a strain exist. Thus, it is believed, for example, that the regions of the various HCV strains serve essentially the same function for the respective strains and that interference with
15 expression of the genetic information will afford similar results in the various strains. This is believed to be so even though differences in the nucleotide sequences among the strains exist.

Accordingly, nucleotide sequences set forth in the
20 present specification will be understood to be representational for the particular strain being described. Homologous or analogous sequences for different strains of HCV are specifically contemplated as being within the scope of this invention.

25 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Antisense oligonucleotides hold great promise as therapeutic agents for the treatment of many human diseases. In most cases, oligonucleotides complementary to specific RNA target sequences bind by Watson-Crick base pairing to pre-mRNA
30 or mature mRNA, inhibiting the flow of genetic information from DNA to protein. In the case of RNA viruses such as HCV, oligonucleotides are designed to specifically hybridize to viral genomic RNA, mRNA, or replicative intermediate RNA, interfering with the function of the RNA such that viral
35 replication or protein expression is modulated.

Numerous recent studies have documented the utility

- 7 -

of antisense oligonucleotides as biochemical tools for studying target proteins. Rothenberg et al., *J. Natl. Cancer Inst.* 1989, 81, 1539-1544; Zon, G. *Pharmaceutical Res.* 1987, 5, 539-549. Because of recent advances in oligonucleotide chemistry, 5 synthesis of nuclease-resistant oligonucleotides, and availability of types of oligonucleotides which exhibit enhanced cell uptake, it is now possible to consider the use of antisense oligonucleotides as a novel form of therapeutics.

For therapeutics, an animal suspected of having an HCV 10 infection or HCV-associated disease is treated by administering oligonucleotides in accordance with this invention. Oligonucleotides may be formulated in a pharmaceutical composition, which may include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in 15 addition to the oligonucleotide. Pharmaceutical compositions may also include one or more active ingredients such as, for example, antimicrobial agents, antiinflammatory agents, anesthetics, and the like in addition to oligonucleotide.

The pharmaceutical composition may be administered in 20 a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration may be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, 25 intraperitoneal or intramuscular injection.

Formulations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be 30 necessary or desirable. Coated condoms may also be useful.

Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be 35 desirable.

Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers,

- 8 -

diluents and other suitable additives.

Dosing is dependent on severity and responsiveness of the condition to be treated, but will normally be one or more doses per day, with course of treatment lasting from several
5 days to several months or until a cure is effected or a diminution of disease state is achieved. Dosage and frequency will vary depending on, for example, body weight of patient and means of administration. Individual doses will normally range from about 0.001 mg to 500 mg, but may be higher or lower.
10 Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates.

The present invention employs oligonucleotides complementary to specific regions of HCV RNA for antisense inhibition of HCV. In the context of this invention, the term
15 "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid or deoxyribonucleic acid. This term includes oligomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages as well as oligomers having non-naturally occurring portions which function similarly. Such
20 modified or substituted oligonucleotides are often preferred over native forms because of properties such as, for example, enhanced cellular uptake and increased stability in the presence of nucleases.

Specific examples of some preferred oligonucleotides
25 envisioned for this invention may contain phosphorothioates, phosphotriesters, methyl phosphonates, chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Most preferred are those with $\text{CH}_2\text{-NH-O-CH}_2$, $\text{CH}_2\text{-N(CH}_3\text{)-O-CH}_2$, $\text{CH}_2\text{-O-N(CH}_3\text{)-CH}_2$, $\text{CH}_2\text{-}$
30 $\text{N(CH}_3\text{)-N(CH}_3\text{)-CH}_2$ and $\text{O-N(CH}_3\text{)-CH}_2\text{-CH}_2$ backbones (where phosphodiester is O-P-O-CH_2). Also preferred are oligonucleotides having morpholino backbone structures. Summerton, J.E. and Weller, D.D. US 5,034,506. In other preferred embodiments, such as the protein-nucleic acid (PNA)
35 backbone, the phosphodiester backbone of the oligonucleotide may be replaced with a polyamide backbone, the bases being bound directly or indirectly to the aza nitrogen atoms of the

- 9 -

polyamide backbone. P.E. Nielsen, M. Egholm, R.H. Berg, O. Buchardt, *Science* 1991, 254, 1497. Other preferred oligonucleotides may contain alkyl, halogen or otherwise substituted sugar moieties comprising one of the following at
5 the 2' position: OH, SH, SCH₃, F, OCN, O(CH₂)_nNH₂ or O(CH₂)_nCH₃ where n is from 1 to about 10; C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF₃; OCF₃; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; SOCH₃; SO₂CH₃; ONO₂; NO₂; N₃; NH₂; heterocycloalkyl; heterocycloalkaryl;
10 aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having
15 similar properties. Oligonucleotides may also have sugar mimetics such as cyclobutyls in place of the pentofuranosyl group. Modified or unusual bases may also be used; most preferred among these is inosine, which is a "universal base" capable of Watson-Crick pairing with A, C, G or T. Other
20 universal bases may also be preferred. Thus, in one embodiment, the oligonucleotides of this invention have a universal base at a position which is complementary to a nucleotide in the HCV RNA which is variable among strains of HCV.

25 All such oligonucleotides are comprehended by this invention so long as they function effectively to hybridize with HCV RNA. The oligonucleotides in accordance with this invention preferably comprise from about 5 to about 50 nucleic acid base units. It is more preferred that such
30 oligonucleotides comprise from about 8 to 30 nucleic acid base units, and still more preferred to have from about 14 to 26 nucleic acid base units. As will be appreciated, a nucleic acid base unit is a base-sugar combination suitably bound to adjacent nucleic acid base unit through phosphodiester or other
35 bonds.

In preferred embodiments, the antisense oligonucleotides are complementary to and hybridizable with at

- 10 -

least a portion of the loop B region or loop C region of the 5'-untranslated region of the HCV RNA. Particularly suitable antisense oligonucleotides comprises, for example, SEQ ID NO: 33, SEQ ID NO: 41, SEQ ID NO: 20, SEQ ID NO: 38, SEQ ID NO: 39, 5 SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, and SEQ ID NO: 45.

In a preferred embodiment, the antisense oligonucleotides are complementary to and hybridizable with at least a portion of the loop F region of the 5'-end untranslated region of an HCV RNA. Particularly suitable antisense 10 oligonucleotide comprises SEQ ID NO: 62.

In a preferred embodiment, the antisense oligonucleotides are hybridizable with the following nucleotide sequence (A) which is present at the 5'-untranslated region of the HCV genome, or with a nucleotide sequence which is highly 15 homologous to said nucleotide sequence, differing from said nucleotide sequence (A) merely in one or two base units:

(A) GCCUCCAGGACCCC.

Such oligonucleotides are at least 14 nucleotides long, preferably 14 to 26 nucleotides long. Thus, the 20 oligonucleotides contain at least an antisense nucleotide sequence to said nucleotide sequence (A).

More preferable oligonucleotides have a nucleotide sequence which is hybridizable to said nucleotide sequence and further contains a nucleotide sequence complementary to the 25 following nucleotide sequence (B) comprising nucleotides 104-129 of the 5'-end untranslated region of an HCV RNA which are originated from HCV genome or to a continuous nucleotide sequence of about 20 mer within the nucleotide sequence B:

(B) CGUGCAGCCUCCAGGACCCCCCUCC

30 (region in bold is equivalent to sequence (A) above).

In other preferred embodiments, the oligonucleotides are hybridizable with at least a portion of the polyprotein translation initiation codon or with at least a portion of the core protein coding region. In a more preferred embodiment, the 35 oligonucleotides contain an antisense nucleotide sequence GGAT which is specifically hybridizable with a nucleotide sequence

- 11 -

AUCC of the genome of HCV or neighbor thereof, which is present at nucleotides 352 to 355 in the core protein coding region near the polyprotein translation initiation codon. Suitable examples of the oligonucleotides hybridizable with at least a portion of the polyprotein translation initiation codon are SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 72, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, and SEQ ID NO: 80, and suitable examples of the oligonucleotides hybridizable with at least a portion of the core protein coding region of an HCV RNA are SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, and SEQ ID NO: 91. Besides, suitable examples of the oligonucleotides hybridizable with a nucleotide sequence of the nucleotide number 352 to 355 (AUCC) of HCV DNA or neighbor thereof are SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86 and SEQ ID NO: 87.

The oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed, however the actual synthesis of the oligonucleotides are well within the talents of the routineer. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioates and alkylated derivatives.

In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA includes not only the sequence information to encode a protein using the three letter genetic code, but also associated ribonucleotides which form regions known to such persons as the 5'-untranslated region, the 3'-untranslated region, and the 5' cap region, as well as ribonucleotides which form various secondary structures. Thus, oligonucleotides may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the coding ribonucleotides. In preferred embodiments, the

- 12 -

oligonucleotide is specifically hybridizable with the HCV 5' end hairpin loop, 5' end 6-base-pair repeats, ORF 3 translation initiation codon (all of which are contained in the 5'-untranslated region), polyprotein translation initiation codon, 5 core protein coding region, 3'-untranslated region, R2 region, 3' hairpin loop or 3' end palindrome region.

The size of the HCV genome is approximately 9400 nucleotides, with a single translational reading frame encoding a polyprotein which is subsequently processed to several 10 structural and non-structural proteins.

Several regions of the HCV genome have been identified as antisense targets in the present invention. It should be noted that sequence availability and nucleotide numbering schemes vary from strain to strain. The 5' untranslated region 15 of HCV consists of approximately 350 nucleotides upstream of the polyprotein translation initiation codon. A hairpin loop present at nucleotides 1-22 at the 5' end of the genome (HCV-1) identified herein as the "5' end hairpin loop" is believed to serve as a recognition signal for the viral replicase or 20 nucleocapsid proteins. Han et al., *Proc. Natl. Acad. Sci.* 1991, 88, 1711-1715. The 5' untranslated region is believed to have a secondary structure which includes six stem-loop structures, designated loops A-F. Loop A is present at approximately nucleotides 13-50, loop B at approximately 25 nucleotides 51-88, loop C at approximately nucleotides 100-120, loop D at approximately nucleotides 147-162, loop E at approximately nucleotides 163-217, and loop F at approximately nucleotides 218-307. Tsukiyama-Kohara et al., *J. Virol.* 1992, 66, 1476-1483. These structures are well conserved between the 30 two major HCV groups.

Three small (12-16 amino acids each) open reading frames (ORFs) are located in the 5'-untranslated region of HCV RNA. These ORFs may be involved in control of translation. The ORF 3 translation initiation codon as denominated herein is 35 found at nucleotides 215-217 of HCV-1 according to the scheme of Han et al., *Proc. Natl. Acad. Sci.* 1991, 88, 1711-1715; and at nucleotides -127 to -125 according to the scheme of Choo et

- 13 -

al., *Proc. Natl. Acad. Sci.* 1991, 88, 2451-2455.

The polyprotein translation initiation codon as denominated herein is an AUG sequence located at nucleotides 342-344 of HCV-1 according to Han et al., *Proc. Natl. Acad. Sci.* 1991, 88, 1711-1715 or at nucleotide 1-3 according to the HCV-1 numbering scheme of Choo et al., *Proc. Natl. Acad. Sci.* 1991, 88, 2451-2455. Extending downstream (toward 3' end) from the polyprotein AUG is the core protein coding region.

The 3' untranslated region, as denominated herein, consists of nucleotides downstream of the polyprotein translation termination site (ending at nt 9037 according to Choo et al.; nt 9377 according to schemes of Han and Inchauspe). Nucleotides 9697-9716 (numbering scheme of Inchauspe for HCV-H) at the 3' terminus of the genome within the 3' untranslated region can be organized into a stable hairpin loop structure identified herein as the 3' hairpin loop. A short nucleotide stretch (R2) immediately upstream (nt 9691-9696 of HCV-H) of the 3' hairpin, and denominated herein "the R2 sequence", is thought to play a role in cyclization of the viral RNA, possibly in combination with a set of 5' end 6-base-pair repeats of the same sequence at nt 23-28 and 38-43. (Inchauspe et al., *Proc. Natl. Acad. Sci.* 1991, 88, 10292-10296) is identified herein as "5' end 6-base-pair repeat". Palindrome sequences present near the 3' end of the genome (nucleotides 9312-9342 according to the scheme of Takamizawa et al., *J. Virol.* 1991, 65, 1105-1113) are capable of forming a stable secondary structure. This is referred to herein as the 3' end palindrome region.

Oligonucleotides useful in the invention are complementary to HCV RNA. Thus, the oligonucleotides whose sequences are shown in Table 1 are believed to be useful against HCV. It is preferred to employ any of these oligonucleotides, or an effective portion thereof, as set forth above, or any of the similar oligonucleotides which persons of ordinary skill in the art can prepare from knowledge of the preferred antisense targets for the modulation of HCV infection.

- 14 -

TABLE 1

**RNA SEQUENCE TARGETS AND ANTISENSE
OLIGONUCLEOTIDES FOR HCV**

[Sequences are from HCV-1 (US) and HCV-J (Japan)]

	SEQ ID	Antisense oligo	Target	Target
	NO:	sequence:	description:	strand:
	1	5'-ATG GTG GAG TGT CGC CCC GTC-3'	5' end hairpin	+
	2	5'-GGA GTG ATC TAT GGT GGA GTG-3'	5' end 6-bp repeat	+
	3	5'-GAT TCG TGC TCA TGG TGC ACG-3'	Polyprotein AUG	+
10	4	5'-TCC AGG CAT TGA GCG GGT TGA-3'	ORF 3 AUG	+
	5	5'-TGG CCT GGA GTG TTT ATC TCC-3'	3'-untranslated	+
	6	5'-GGG GTA GGC ATC TAC CTG CTC-3'	3' palindrome	-
	7	5'-CGC CCC CAT CAG GGG GCT GGC-3'	5' end hairpin	+
	8	5'-TTC ATG GTG GAG TGT CGC CCC-3'	5' end hairpin	+
15	9	5'-GTT CCT CAC AGG GGA GTG ATT-3'	5' untranslated	+
	10	5'-TAC TAA CGC CAT GGC TAG ACG-3'	5' untranslated	+
	11	5'-CTA TGG CTC TCC CGG GAG GGG-3'	5' untranslated	+
	12	5'-CCA CTA TGG CTC TCC CGG GAG-3'	5' untranslated	+
	13	5'-CGG TGT ACT CAC CGG TTC CGC-3'	5' untranslated	+
20	14	5'-CTG GCA ATT CCG GTG TAC TCA-3'	5' untranslated	+
	15	5'-GGG GCA CGC CCA AAT CTC CAG-3'	5' untranslated	+
	16	5'-CCT TTC GCG ACC CAA CAC TAC-3'	5' untranslated	+
	17	5'-CCC TAT CAG GCA GTA CCA CAA-3'	5' untranslated	+
	18	5'-CTC CCG GGG CAC TCG CAA GCA-3'	5' untranslated	+
25	19	5'-CAT GGT GCA CGG TCT ACG AGA-3'	Polyprotein AUG	+
	20	5'-GTC CTG GAG GCT GCA CGA CA-3'	5' untranslated	+
	21	5'-TTT AGG ATT CGT GCT CAT GGT-3'	Polyprotein AUG	+
	22	5'-GAG TGG TTA GCC CAA TCT TCA-3'	3' untranslated	+
	23	5'-TAT TGG CCT GGA GTG GTT AGC-3'	R2	+
30	24	5'-AGG GAA TGG CCT ATT GGC CTG-3'	R2/3' hairpin	+

The oligonucleotides of this invention can be used in diagnostics, therapeutics and as research reagents and kits. Since the oligonucleotides of this invention hybridize to RNA from HCV, sandwich and other assays can easily be constructed to exploit this fact. Provision of means for detecting hybridization of oligonucleotide with HCV or HCV RNA present in a sample suspected of containing it can routinely be accomplished. Such provision may include enzyme conjugation,

- 15 -

radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of HCV may also be prepared.

The following specific examples are given for illustrative purposes only and are not intended to limit the invention.

EXAMPLES

Example 1

Oligonucleotide synthesis: Unmodified DNA oligonucleotides were synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine. β -cyanoethyl-diisopropyl-phosphoramidites were purchased from Applied Biosystems (Foster City, CA). For phosphorothioate oligonucleotides, the standard oxidation bottle was replaced by a 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation cycle wait step was increased to 68 seconds and was followed by the capping step.

2'-O-methyl oligonucleotides were synthesized using 2'-O-methyl β -cyanoethyl-diisopropyl-phosphoramidites (Chemgenes, Needham MA) and the standard cycle for unmodified oligonucleotides, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds. The 3'-base used to start the synthesis was a 2'-deoxyribonucleotide.

2'-O-propyl oligonucleotides were prepared from 2'-deoxy-2'-O-propyl ribosides of nucleic acid bases A, G, U(T), and C which were prepared by modifications of literature procedures described by B.S. Sproat, et al., *Nucleic Acids Research* 18:41-49 (1990) and H. Inoue, et al., *Nucleic Acids Research* 15:6131-6148 (1987).

After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides were purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Analytical gel electrophoresis was

- 16 -

accomplished in 20% acrylamide, 8 M urea, 45 mM Tris-borate buffer, pH 7.0.

Example 2

Transcription and translation of HCV RNA in genetically engineered cells: A recombinant DNA vector capable of expressing HCV genes in mammalian cells is constructed using standard genetic engineering methods. A cDNA fragment representing the HCV mRNA or genomic transcript is placed behind an inducible eukaryotic promotor such as the LTR from mouse mammary tumor virus in such a way that transcription of the HCV cDNA begins at the appropriate nucleotide position. At the 3' end of the gene, a polyadenylation signal is incorporated to ensure termination at the appropriate nucleotide position. It may be advantageous to modify the coding sequence by insertion of an in-frame reporter domain (e.g., the enzymatically active domain of the firefly luciferase gene) which can simplify detection procedures for expression of the fusion protein. The vector also contains one or more selectable genetic markers such as neomycin resistance.

The described vector is introduced into mammalian cells using a standard calcium chloride transfection procedure. Cells containing transfected DNA are identified by growth in the presence of selective agents such as neomycin, and cloned by limiting dilution. Expression of HCV RNA in cloned transfectants can be verified using any one of a number of assays such as northern blots, RNA polymerase chain reaction, or nuclease protection. Protein expression can be verified using western blotting or immune precipitation with specific HCV antibodies, or by monitoring for the presence of detectable enzymatic activity resulting from the incorporation of an assayable reporter domain. If an inducible promotor such as the MMTV LTR is used in construction of the vector, a glucocorticoid inducer such as dexamethasone should be added to the transfected cells prior to assays in order to induce gene expression.

- 17 -

Example 3

Evaluation of antisense oligonucleotide inhibition of HCV gene expression from genetically engineered cells: Mammalian cells transfected with expression vectors such as those described in
5 Example 2 are incubated overnight in medium containing antisense oligonucleotides. After oligonucleotide treatment, cells are treated with dexamethasone in order to induce expression of HCV gene products. After a suitable incubation period (4-24 hours) cells are harvested, and expression of
10 specific HCV polypeptide can be detected immunologically using specific antisera in a western blot or immunoprecipitation assay. If the cells contain a vector containing a reporter domain, such as that for firefly luciferase, fused in-frame with the HCV polyprotein, cell extracts can be harvested and
15 evaluated for enzymatic activity of the reporter domain.

Example 4

Transcription and translation of HCV RNA from cytoplasmic virus vectors: A cDNA fragment representing the HCV mRNA or genomic transcript is placed behind a Vaccinia virus promotor in such
20 a way that transcription of the HCV cDNA begins at the appropriate nucleotide position. At the 3' end of the gene, a polyadenylation signal is incorporated to ensure termination at the appropriate nucleotide position. It may be advantageous in some instances to modify the coding sequence by insertion of an
25 in-frame reporter domain (e.g., the enzymatically active domain of the firefly luciferase gene) which can simplify detection procedures for expression of the fusion protein.

Incorporation of the expression unit into the genome of a cytoplasmic replicating DNA virus such as Vaccinia is
30 facilitated by inclusion of sequences upstream and downstream of the expression unit which are homologous to the Vaccinia virus genome. Co-transfection of vector into Vaccinia virus-infected mammalian cells can result in homologous recombination of vector with Vaccinia. If a suitable enzymatic marker such
35 as β -galactosidase is present at the appropriate recombination site in the virus, then recombinant plaques can be identified

- 18 -

by a lack of color under appropriate substrate conditions. Cloned virus can be propagated in appropriate host mammalian cell lines and expression of HCV gene products verified as described in Example 2.

5 Example 5

Evaluation of antisense oligonucleotide inhibition of HCV gene expression from cytoplasmic virus vectors in mammalian cells: Mammalian cells are incubated overnight in medium containing antisense oligonucleotides. After oligonucleotide treatment,
10 cells are infected with recombinant Vaccinia virus expressing HCV gene products. After a suitable incubation period (4-24 hours) cells are harvested, and expression of specific HCV polypeptide can be detected immunologically using specific antisera in a western blot or immunoprecipitation assay. If
15 the cells contain a vector containing a reporter domain, such as that for firefly luciferase, fused in-frame with the HCV polyprotein, cell extracts can be harvested and evaluated for enzymatic activity of the reporter domain.

Example 6

20 Evaluation of antisense oligonucleotide inhibition of HCV particle assembly in cells transfected with HCV genes or infected with cytoplasmic virus vectors expressing HCV genes: HCV genomic RNA and protein are expressed in cells transfected with HCV cDNA expression vectors, or in cells infected with
25 Vaccinia virus vectors expressing the HCV cDNA. It is likely that the RNA genomes and proteins will associate to form HCV-like particles. The presence of these particles can be verified using electron microscopy. To evaluate the effects of oligonucleotides complementary to presumed packaging signals of
30 the viral RNA on particle assembly, specific biochemical assays can be developed to measure the appearance of extracellular particles containing both HCV nucleic acid and proteins.

Mammalian cells transfected with expression vectors such as those described in Example 2 are incubated overnight in
35 medium containing antisense oligonucleotides. After

- 19 -

oligonucleotide treatment, cells are treated with dexamethasone in order to induce expression of HCV gene products. After a suitable incubation period (4-24 hours) extracellular fluid from treated cells is harvested, and particles are concentrated
5 by pelleting in the ultracentrifuge. Proteins and nucleic acids are extracted from the pellet and quantitated by northern blot and western blot analysis respectively as described in Examples 4 and 5. A similar procedure could be used to monitor effects of oligonucleotide treatment on virus particle assembly
10 resulting from infection of cells with recombinant Vaccinia virus expressing the HCV polyprotein.

Example 7

Screening of oligonucleotides by in vitro translation assay:

1. Preparation of HCV RNA to be used for translation 15 in vitro:

An RNA having a sequence homologous to the base number 1-686 of HCV gene nucleotide sequence was prepared in the following manner, wherein the stop codon (TGA) was added to 3'-terminus.

20 (1) Preparation of template HCV-cDNA for polymerase chain reaction (PCR):

Based on a cDNA nucleotide sequence prepared by the present inventors by cloning from serum of a Japanese patient of Hepatitis C, said cDNA being possibly coding for
25 full length HCV amino acid sequence, there was cloned a cDNA containing 686 nucleotide sequence which comprised the full length 5'-untranslated region of HCV gene (341 nucleotide sequence) and a core region (345 nucleotide sequence) continued thereto at 5'-terminus by a known technique, and the clone was
30 used as a template for the PCR procedure in the following (3). The nucleotide numbers for this cDNA sequence have been found to correspond well to those of Han et al. (*Proc. Natl. Acad. Sci.* 1991, 88, 1711-1715).

(2) Preparation of a primer for PCR:

35 There were prepared a sense primer comprising 41 nucleotide sequence which contained 7 bases including EcoRI

- 20 -

cleavage site, 20 bases having a function as T7 promoter and 14 bases (nucleotide number 1-14) of HCV nucleotide sequence in this order from the 5'-terminus, and also an antisense primer comprising 27 nucleotide sequence which contained 9 bases including EcoRI cleavage site, 3 bases which are complementary to the stop codon (TGA) and 15 bases which are complementary to the region of the base number 672-686 of HCV nucleotide sequence in this order from the 5'-terminus by a solid phase phosphoamidite method with Cyclone Plus DNA Synthesizer (manufactured by MilliGen/Biosearch).

(3) Preparation of template DNA for synthesis of RNA by PCR:

By using the cDNA obtained in the above (1) as the template, the PCR (20 cycles) proceeded with the primers of the above (2). The PCR was done under the conditions of denaturation: 94°C for one minute, annealing: 55°C for 2 minutes, polymerase reaction: 72°C for 2 minutes. The thus obtained DNA fragment was treated with EcoRI and inserted into EcoRI site of pUC19, and *E. coli* JM 109 strain was transformed with the resultant recombinant plasmid by a conventional method. By sequencing the part inserted with the recombinant plasmid as to the plural clones in colonies thus obtained by dideoxy method, it was confirmed that the HCV-origin 686 nucleotide sequences inserted by the plasmids from all clones conformed well with the corresponding region of the template cDNA. A plasmid obtained from one of the clones was designated "pUIA1".

(4) Preparation of RNA having a part of the nucleotide sequence of HCV gene:

A fragment inserted with the above nucleotide sequence was taken out from the pUIA1 by treating it with EcoRI, and by using said fragment as a template, an RNA was synthesized with MEGAscript in vitro Transcription Kit (manufactured by Ambion), and thereby there was obtained an RNA fragment having 698 nucleotide sequence which comprised 1-686 nucleotide sequence part of HCV nucleotide sequence, stop codon (UGA) and 9 bases including EcoRI cleavage site in this order from 5'-terminus.

- 21 -

This fragment was designated "R-IA-1". The nucleotide sequence of the 686 bases derived from HCV in said R-IA-1 is shown in the accompanying Figure 1.

2. Synthesis of HCV core protein in cell-free translation system:

An HCV core protein was translated from R-IA-1 in cell-free system by using a rabbit reticulocyte lysate and the expression was confirmed by ELISA as follows.

(1) Construction of ELISA system for quantitatively determining HCV core protein:

The core region of HCV was directly expressed in *E. coli* by a conventional method. A mouse was immunized with the expressed protein thus obtained, and two kinds of monoclonal antibodies, RJC4-1 (IgM type) and RJC4-2 (IgG type) were obtained therefrom by treating it by a conventional method. Said monoclonal antibody RJC4-1 was diluted with 10mM PBS, and the diluted RJC4-1 (concentration 50 μ g/ml, 50 μ l) was added to each well of MaxiSorp F8 plate (Nunc) and fixed by allowing to stand at 4°C overnight, and thereafter the remaining antibody solution was removed by suction from the well. A PBS containing 1 % calf serum albumin (150 μ l) was added to each well and allowed to stand at 4°C overnight to effect blocking of the antibody and then subjected to washing. The core protein to be tested, prepared above using rabbit reticulocyte extract, was diluted in an appropriate concentration with a PBS containing 1 % calf serum albumin, and the diluted core protein (50 μ l) was added to each well, and the mixture was subjected to reaction at room temperature for 2 hours and then to washing. Thereafter, the antibody RJC4-2 (50 μ l) bound with a horseradish peroxidase was added to each well, and the mixture was subjected to reaction at 37°C for one hour and then to washing. Lastly, an aqueous solution of 3,3',5,5'-tetramethylbenzidine (50 μ l) was added to each well, and the mixture was subjected to reaction at room temperature for 15 minutes, and then the reaction was chilled with 1N sulfuric acid. Immediately, the absorbance of the reaction mixture at 450 nm was measured. As a result, it was found that the HCV

- 22 -

core protein could be determined quantitatively by ELISA.

(2) Expression of HCV core protein with a rabbit reticulocyte lysate:

Each of a solution of R-IA-1 (20 pmol) in TE (10 μ l) and a TE (10 μ l) containing no RNA was mixed with an aqueous solution of methionine (2 μ l) (the final concentration of methionine, 10 μ M). To each mixture (12 μ l) was added a rabbit reticulocyte lysate (In Vitro Translation Kit, manufactured by STRATAGENE, 20 μ l), and the mixture was incubated at 30°C for 2 hours. The reaction mixture was fold-diluted and then the core protein was quantitatively determined by ELISA. As a result, it was confirmed that the HCV core protein was synthesized in the positive control, but no HCV core protein was found in the negative control.

15

3. Search of target region of antisense compounds:

Oligonucleotides complementary to the 5'-untranslated region were screened as follows for ability to inhibit the translation of HCV core protein in vitro.

20 (1) Preparation of synthetic antisense DNA oligonucleotides:

Antisense oligonucleotides were prepared by a solid phase phosphoamidite method as in Example 1 (for oligonucleotides designated "IA-") or using a Cyclone Plus DNA Synthesizer (manufactured by MilliGen/Biosearch) (for oligonucleotides designated "CAS-"). The product thus obtained was treated with phenol and subjected to ethanol precipitation. The precipitate was dissolved in 10mM Tris-HCl (pH 8.0) - 1 mM EDTA solution for use in the subsequent procedure.

30 The antisense oligonucleotides were each 20 nucleotides in length. The "CAS-" or "IA-" number used to denominate each sequence refers to the number of the 5'-most nucleotide of the corresponding HCV RNA target sequence shown in the accompanying Fig. 1.

35 (2) Evaluation of inhibitory activity of the antisense oligonucleotides:

R-IA-1 (20 pmol) and an antisense DNA to be tested

- 23 -

(100 pmol) were mixed in TE (the final volume, 10 μ l), and the mixture was allowed to stand at room temperature for 10 minutes. To the solution was added 10 mM aqueous methionine solution (2 μ l), and further to the mixture (12 μ l) was added
5 a rabbit reticulocyte lysate (In Vitro Translation Kit, manufactured by STRATAGENE, 20 μ l), and the mixture was incubated at 30°C for 2 hours. After the reaction was completed, the core protein produced in the reaction mixture was quantitatively determined by ELISA, and there was
10 calculated the ratio of the amount of the core protein in said reaction mixture to that of the core protein produced in the TE containing no antisense DNA. The inhibitory activity (%) was calculated by deducting the above-obtained ratio from 1 (one) and expressing the resultant as a percentage.

15 (3) Screening for target regions effective for inhibition of the growth of HCV:

Antisense oligonucleotides were synthesized which are complementary to target sequences located at 10-nucleotide intervals from nucleotide 1 to 339 in the HCV RNA 5'-
20 untranslated region. The sequences of these oligonucleotides, CAS-1 through CAS-320, are shown in Table 2.

- 24 -

Table 2
Antisense oligonucleotides to HCV

Oligo	Sequence	SEQ ID NO:
CAS-1	GCC CCG AAT CGG GGG CTG GC	26
5 CAS-10	TGG AGT GTC GCC CCC AAT CG	27
CAS-20	TGA TCT ATG GTG GAG TGT CG	28
CAS-30	CAC AGG GGA GTG ATC TAT GG	29
CAS-40	AGT AGT TCC TCA CAG GGG AG	30
CAS-50	GCG TGA AGA CAG TAG TTC CT	31
10 CAS-60	GAC GCT TTC TGC GTG AAG AC	32
CAS-70	GCC ATG GCT AGA CGC TTT CT	33
CAS-80	TCA TAC TAA CGC CAT GGC TA	34
CAS-90	TGC ACG ACA CTC ATA CTA AC	35
CAS-100	TCC TGG AGG CTG CAC GAC AC	36
15 CAS-101	GTC CTG GAG GCT GCA CGA CA	20
CAS-102	GGT CCT GGA GGC TGC ACG AC	37
CAS-104	GGG GTC CTG GAG GCT GCA CG	38
CAS-106	GGG GGG TCC TGG AGG CTG CA	39
CAS-108	AGG GGG GGT CCT GGA GGC TG	40
20 CAS-110	GGA GGG GGG GTC CTG GAG GC	41
CAS-110-I-119	GGA GGG GGG GIC CTG GAG GC	42
CAS-110-G-119	GGA GGG GGG GGC CTG GAG GC	43
CAS-112	CGG GAG GGG GGG TCC TGG AG	44
CAS-114	CCC GGG AGG GGG GGT CCT GG	45
25 CAS-116	CTC CCG GGA GGG GGG GTC CT	46
CAS-118	CTC TCC CGG GAG GGG GGG TC	47
CAS-120	GGC TCT CCC GGG AGG GGG GG	48
CAS-130	AGA CCA CTA TGG CTC TCC CG	49
CAS-140	CCG GTT CCG CAG ACC ACT AT	50
30 CAS-150	GGT GTA CTC ACC GGT TCC GC	51
CAS-160	TGG CAA TTC CGG TGT ACT CA	52
CAS-170	CCG GTC GTC CTG GCA ATT CC	53
CAS-180	AAG AAA GGA CCC GGT CGT CC	54
CAS-190	GGG TTG ATC CAA GAA AGG AC	55
35 CAS-200	GGC ATT GAG CGG GTT GAT CC	56
CAS-210	CAA ATC TCC AGG CAT TGA GC	57
CAS-220	GGG GCA CGC CCA AAT CTC CA	58
CAS-230	CAG TCT CGC GGG GGC ACG CC	59
CAS-240	ACT CGG CTA GCA GTC TCG CG	60
40 CAS-250	ACC CAA CAC TAC TCG GCT AG	61
CAS-260	GCC TTT CGC GAC CCA ACA CT	62
CAS-270	GTA CCA CAA GGC CTT TCG CG	63
CAS-280	CTA TCA GGC AGT ACC ACA AG	64
CAS-290	CGC AAG CAC CCT ATC AGG CA	65
45 CAS-300	CCG GGG CAC TCG CAA GCA CC	66
CAS-310	ACG AGA CCT CCC GGG GCA CT	67
CAS-320	TGC ACG GTC TAC GAG ACC TC	68

The inhibitory activity of these antisense oligonucleotides was tested using the HCV in vitro core protein

- 25 -

translation assay. Oligonucleotide CAS-110, which is complementary to a portion of loop C, was found to cause greater than 80% inhibition and is most preferred. These results are shown in Figure 2.

5 (4) Analysis at around the base number 100-130 in more detail:

Additional oligonucleotides which are complementary to the region from nucleotide 100 to 140 of HCV RNA, which includes the loop C region, were synthesized and tested as above. These
10 oligonucleotides are shown in Table 2. As shown in Figure 2, oligonucleotides CAS-104, CAS-106, and CAS-108 were found to inhibit HCV core protein translation in vitro by 70% or more and are preferred. The antisense oligonucleotides complementary to the 26-base region of HCV RNA from nucleotides
15 104 to 129 showed strong inhibitory activity against the translation of the HCV-RNA in comparison with the antisense oligonucleotides complementary to other regions of 5'-untranslated region. Oligonucleotides hybridizable with this region are therefore preferred.

20 (5) Evaluation of antisense oligonucleotides wherein the base number 119 was substituted by inosine:

Because the nucleotide at position 119 in the loop C region has a high variation rate among HCV strains, various antisense oligonucleotides were prepared wherein the adenosine
25 at this position was substituted by the "universal base" inosine in order to evaluate whether the substituted oligonucleotides would be effective for the inhibition of various virus strains as follows.

Among the nucleotide sequence of CAS-110, the
30 thymidine corresponding to adenosine at nucleotide number 119 was replaced by inosine to give CAS-110-I-119. As a reference, there was also prepared CAS-110-G-119 wherein said thymidine was replaced by guanosine so as to make an artificial mismatch. These sequences are shown in Table 2. The inhibitory activity
35 of these oligonucleotides was evaluated as above. As a result, CAS-110-I-119 showed an inhibitory activity of more than 70%

- 26 -

similar to CAS-110, but CAS-110-G-119 showed much lower activity. CAS-110-I-119 is therefore preferred. It is likely from the result that the compound obtained by replacing thymidine with inosine would be effective against other virus strains in which adenosine at position 119 is replaced by another nucleotide.

(6) Evaluation of 2'-O-methyl antisense oligonucleotides:

The binding affinity of antisense oligonucleotides for their target sequence is enhanced by methoxylation of the 2'-position of the sugar moiety in the antisense oligonucleotide. 2'-O-methylated oligonucleotides were prepared having the sequences shown in Table 2 (other than the two substituted by inosine) and their inhibitory activity was evaluated. In most cases, 2'-O-methylated oligonucleotides were similar in inhibitory activity to their unmodified counterparts. Some oligonucleotides (CAS-80, CAS-360) appeared to be less active when 2'-O-methylated, and CAS-260 hybridizing to the loop F region appeared to be significantly more active when 2'-O-methylated, showing greater than 75% inhibition. This sequence is therefore preferred. Activities of some of the tested oligonucleotides are shown in Figure 3.

Example 8

Evaluation of inhibitory activity of antisense oligonucleotides which are complementary to the nucleotide sequence at around the polyprotein translation initiation codon and adjacent core protein coding region:

(1) In order to evaluate the inhibitory activity of antisense oligonucleotides which are complementary to the nucleotide sequence around the translation initiation codon (nucleotide number 342-344) of HCV-RNA and adjacent core protein coding region, a series of 20mer antisense oligonucleotides were prepared which are complementary to the region from nucleotide 320 to nucleotide 379. Of these, CAS-324 through CAS-344 contain all or part of the sequence CAT which is complementary to the AUG initiation codon itself. The

- 27 -

nucleotide sequence of these antisense oligonucleotides are shown in the accompanying Table 3.

Table 3
Antisense oligonucleotides to HCV

5	Oligo	Sequence	% Inhibition	SEQ ID NO:
	CAS-320	TGC ACG GTC TAC GAG ACC TC	3	68
	CAS-322	GGT GCA CGG TCT ACG AGA CC	5	69
	CAS-324	ATG GTG CAC GGT CTA CGA GA	31	70
	CAS-326	TCA TGG TGC ACG GTC TAC GA	39	71
10	CAS-328	GCT CAT GGT GCA CGG TCT AC	71	72
	CAS-330	GTG CTC ATG GTG CAC GGT CT	38	73
	CAS-332	TCG TGC TCA TGG TGC ACG GT	5	74
	CAS-334	ATT CGT GCT CAT GGT GCA CG	39	75
	CAS-336	GGA TTC GTG CTC ATG GTG CA	98	76
15	CAS-338	TAG GAT TCG TGC TCA TGG TG	99	77
	CAS-340	TTT AGG ATT CGT GCT CAT GG	97	78
	CAS-342	GGT TTA GGA TTC GTG CTC AT	96	79
	CAS-344	GAG GTT TAG GAT TCG TGC TC	99	80
	CAS-344-i1	GAG GTT TAG GAT TIG TGC TC	95	81
20	CAS-344-i3	GIG GTT TIG GAT TIG TGC TC	90	82
	CAS-344-i5	GIG GTT TIG GAI IIG TGC TC	51	83
	CAS-346	TTG AGG TTT AGG ATT CGT GC	98	84
	CAS-348	CTT TGA GGT TTA GGA TTC GT	98	85
	CAS-350	TTC TTT GAG GTT TAG GAT TC	99	86
25	CAS-352	TTT TCT TTG AGG TTT AGG AT	99	87
	CAS-354	GTT TTT CTT TGA GGT TTA GG	91	88
	CAS-356	TGG TTT TTC TTT GAG GTT TA	86	89
	CAS-358	TTT GGT TTT TCT TTG AGG TT	83	90
	CAS-360	CGT TTG GTT TTT CTT TGA GG	81	91

30 The inhibitory activity of these 21 antisense oligonucleotides was evaluated in the same manner as above at the concentration of 40 pmol of antisense oligonucleotides. As shown in Table 3, antisense oligonucleotides CAS-328, CAS-336, CAS-338, CAS-340, CAS-342, CAS-344, CAS-346, CAS-348, CAS-350, CAS-352, CAS-354, CAS-356, CAS-358 and CAS-360 showed an inhibitory activity of greater than 70%, and are preferred. Of these, CAS-336, CAS-338, CAS-340, CAS-342, CAS-344, CAS-346, CAS-348, CAS-350 and CAS-352 showed an extremely high inhibitory activity of over 95% and are most preferred. Among these, CAS-346 through CAS-360 hybridize to the core protein coding region immediately adjacent to the translation initiation codon and are not complementary to the AUG itself,

- 28 -

but still showed an extremely high inhibitory activity. On the other hand, the 6 antisense oligonucleotides CAS-324, CAS-326, CAS-328, CAS-330, CAS-332, and CAS-334 are complementary to the translation initiation codon, but showed lower inhibitory activity than the above 9 most active antisense sequences.

The HCV target sequence regions complementary to the above 9 most active antisense oligonucleotides have in common the four nucleotides from number 352 to 355 in the core protein coding region near the polyprotein translation initiation codon. Thus, it is suggested that it is useful to include these four base units in order to inhibit the translation. Accordingly, oligonucleotides comprising the sequence GGAT are preferred embodiments of the invention.

(2) Evaluation of antisense oligonucleotides wherein the nucleotides known to be variable among strains were substituted by inosine:

It is known that in the nucleotide sequences in the core protein coding region near the translation initiation codon, variation of bases among strains occasionally occurs at the nucleotides 350, 351, 352, 356 and 362. Based on this knowledge, it was studied whether substitution of these bases by the "universal base" inosine would be effective for inhibition of various viruses.

There was prepared an antisense DNA by substituting the base at base number 350 in CAS-344 by inosine, which was designated CAS-344-il. Likewise, there was prepared an antisense DNA wherein three bases at base numbers 350, 356 and 362 were substituted by inosine, which was designated CAS-344-i3, and an antisense DNA wherein five bases at base numbers 350, 351, 352, 356, and 362 were substituted by inosine, which was designated CAS-344-i5. The inhibitory activity of these antisense oligonucleotides was evaluated as in the above (1). As a result, the CAS-344-il and CAS-344-i3 showed high inhibitory activity, which suggests that the antisense oligonucleotides having up to about three inosine substituents of sequence CAS-344 may show high inhibitory activity. These oligonucleotides are preferred. Their inhibitory activities are

shown in the accompanying Table 3.

Example 9

Evaluation of antisense DNA in HCV core protein expression cells:

5 (1) Preparation of phosphorothioate oligonucleotides:

Because sequences CAS-110, CAS-260, and CAS-344 showed high inhibitory activity as phosphodiester (P=O) in the test of in vitro translation, the corresponding phosphorothioate (P=S) oligonucleotides were prepared. These oligonucleotides are designated by adding "S" after the name of each parent
10 oligonucleotide, like "CAS-110S", "CAS-260S", and the like. As a negative control, an oligonucleotide having random sequence was prepared.

(2) Preparation of liver cell transformant:

15 An expression plasmid was prepared by inserting a gene (1.3 kbp) coding for 5' NCR-Core-env region of HCV gene by a conventional method.

The thus prepared expression plasmid was transfected into a human liver cell strain (H8Ad17) by lipofectin method.

20 A chemical resistant strain was selected on the basis of the chemical resistant marker gene (G418) inserted into the expression plasmid, and thereby, there was obtained the desired liver cell transformant which expressed HCV core protein.

(3) Detection system for core protein which was
25 expressed by the liver cell transformant:

The core protein expressed by the liver cell transformant was detected by ELISA method using an anti-HCV core-mouse monoclonal antibody as the solid phase antibody; an anti-HCV human polyclonal antibody as the primary antibody; and
30 an HRP (horseradish peroxidase)-conjugated anti-human IgG-mouse monoclonal antibody as the secondary antibody. By using this detection system, the core protein expressed by the liver cell transformant was measured.

(4) Evaluation of antisense oligonucleotides:

35 The liver cell transformant (2.5×10^5 cells) were inoculated on 6-well plates, and the cells were fixed thereon.

- 30 -

To each plate was added each of the above-obtained five antisense oligonucleotides (each in a concentration of 5 μ M). After two days, the cells were harvested and counted. The cells were washed once and lysed with a cell lytic agent, and then, 5 the inhibitory activity was measured by ELISA method.

Setting that the inhibition rate 0% corresponds to the amount of the core protein in case of no addition of an antisense compound, the inhibitory activities of the five P=S antisense oligonucleotides were calculated. As a result, all of 10 the CAS-110S, CAS-260S, CAS-344S and CAS-345S showed inhibitory activities of approximately 30-45% in this in vivo assay. The cell toxicity of these antisense oligonucleotides was also checked. As a result, no cell toxicity was observed in all of these antisense oligonucleotides.

15 Example 10

Evaluation of oligonucleotides in modified in vitro core protein translation assay:

The assay described in Example 7 was modified to eliminate the PCR amplification step by construction of a T7- 20 HCV-core-env fusion plasmid. A T7 expression plasmid was constructed in which the Hind III to Bam HI fragment containing HCV 5' noncoding region-core sequences was inserted into plasmid pGEM4Z. The resulting plasmid was linearized with Bam HI and transcribed by T7 RNA polymerase. 35 S-labeled in vitro 25 translation products were analyzed by SDS-polyacrylamide gel electrophoresis. The optimal amount of T7 RNA transcript for use in translation assays was determined to be approximately 2.2 pmol RNA per reaction. In vitro translation of HCV RNAs of different sizes also yielded products of the expected sizes.

30 A number of phosphodiester (unmodified) oligonucleotides equivalent to those previously evaluated as described in Example 7 were evaluated in the modified in vitro translation assay. Oligonucleotides were resynthesized and were tested at a molar ration of 20:1. As shown in Figure 4, 35 oligonucleotides IA-80, IA-110, IA-140 and IA-360 (identical to the previously tested CAS-80, CAS-110, CAS-140 and CAS-360

- 31 -

sequences, respectively; the "IA" or "CAS" prefix indicates different lots synthesized at different facilities) showed activity in the modified assay comparable to that described in the previous examples. Oligonucleotides IA-140, IA-260 and IA-300 (identical to CAS-140, CAS-260 and CAS-300 sequences tested above) did not show good inhibition in this assay. IA-110 and IA-360 showed the best activity and the IA-80 sequence also was inhibitory in this assay, though the degree of inhibition seen with this oligonucleotide was influenced by the RNA template used in the assay.

Oligonucleotides with 2'-O-methyl modifications:

Oligonucleotide sequences previously tested as unmodified phosphodiester (P=O) compounds were synthesized as uniform 2'-O-methyl/P=O and tested in the modified in vitro translation assay. Results are shown in Figure 5. Oligonucleotides IA-110, 112, 260, 325 and 340 showed inhibitory activity in agreement with previous results obtained with P=O oligonucleotides and are preferred. As found using the original assay system, oligonucleotide 260 was more active in 2'-O-methyl/P=O form than as unmodified phosphodiester.

A panel of uniformly 2'-O-methylated phosphodiester oligonucleotides complementary to loop C sequences was evaluated using the modified in vitro translation assay to identify the oligonucleotide with the greatest inhibitory activity. A second panel of 2'-O-methylated phosphodiester oligonucleotides complementary to the polyprotein initiation codon region was also tested. The results of these assays are shown in Figures 5 and 6. These results confirmed that antisense oligonucleotides complementary to the loop C (around nucleotide 110) and polyprotein translation initiation codon (around nucleotide 340) and adjacent core protein coding region show good inhibitory activity. Such oligonucleotides are preferred.

Evaluation of phosphorothioate (P=S) oligonucleotides:

Phosphorothioate oligonucleotides IA-110 and IA-340 with 2'-O-methyl modifications throughout were evaluated using the modified in vitro translation assay. A comparison of

- 32 -

inhibitory activities of phosphorothioate (P=S), phosphodiester (P=O), 2'-O-me/P=S and 2'-O-me/P=O oligonucleotides was performed. Randomized oligonucleotides (P=S R, 2'-O-Me/P=S R, 2'-O-Me/P=O R) were included in the assays to demonstrate
5 specificity. All IA-110 oligonucleotides, regardless of modification, showed similar ability to inhibit HCV core protein translation. The randomized 110 sequence also showed comparable inhibitory activity, though randomization was not absolute because 13 of the 20 nucleotides in this sequence are
10 G. Oligonucleotide 340 showed sequence-specific inhibition of HCV core protein translation since randomized 340 oligonucleotides showed considerably less inhibitory activity than antisense oligonucleotides. P=O, 2'-O-Me/P=O or 2'-OMe/P=S oligonucleotides (340 sequence) showed similar near-total
15 reduction in HCV core protein translation which was concentration-dependent, as shown in Figure 7.

Because phosphorothioate oligonucleotides tended to show some degree of nonspecific inhibition of in vitro translation in the above assay, a number of phosphorothioates
20 were rescreened in an assay in which RNase H treatment was carried out before the in vitro translation. 2.2 pmol RNA, 4.4 pmol antisense oligonucleotide and 0.23 units RNase H were combined in a total volume of 4 μ l in RNase H buffer consisting of 40 mM Tris HCl, pH 8.0, 20 mM MgCl₂, 200 mM KCl, and 10%
25 sucrose. The reaction was carried out for 30 minutes at 37 °C. In vitro translation and SDS-PAGE were carried out as described in previous examples. RNase H is activated to cleave target RNA only when oligonucleotide is hybridized to the RNA. Both P=O and P=S, but not 2'-O-methyl, oligonucleotides are able to
30 activate RNase H cleavage of RNA. RNA which has been cleaved is not translated into protein. Thus inhibition of translation in this assay indicates successful binding of oligonucleotide to target RNA. Randomized P=S control sequences did not show activity in this assay, demonstrating that they do not bind to
35 the RNA target. Results are shown in Figure 8.

- 33 -

Example 11**2'-O-propyl and other additional oligonucleotides:**

The additional P=S, P=O and 2'-modified oligonucleotides (modified throughout) shown in Table 4 were synthesized. The

5 2'-O-propyl oligonucleotides were tested in the modified in vitro translation assay and compared to 2'-O-methyl oligonucleotides having the same sequence. As shown in Figure 9, in most cases the 2'-O-propyl oligonucleotides inhibited HCV core protein translation to approximately the same extent as

10 their 2'-O-methyl counterparts. Most active sequences were IA-110, IA-260 and IA-340; these are preferred embodiments of the invention. In the case of IA-360, the 2'-O-propyl oligonucleotide had greater inhibitory activity than the 2'-O-methyl version.

Table 4
Antisense oligonucleotides to HCV

Oligo	Sequence	Location on HCV	Modifications	SEQ ID NO:
5	IA-1 GCC CCG AAT CGG GGG CTG GC	1-19	P=O/2', -OMe	26
	IA-10 TGG AGT GTC GCC CCC AAT CG	10-29	P=S	27
	IA-20 TGA TCT ATG GTG GAG TGT CG	20-39	P=S	28
	IA-30 CAC AGG GGA GTG ATC TAT GG	30-49	P=S	29
	IA-40 AGT AGT TCC TCA CAG GGG AG	40-59	P=S	30
10	IA-50 GCG TGA AGA CAG TAG TTC CT	50-69	P=S	31
	IA-60 GAC GCT TTC TGC GTG AAG AC	60-79	P=S	32
	IA-70 GCC ATG GCT AGA CGC TTT CT	70-89	P=S	33
	IA-80 TCA TAC TAA CGC CAT GGC TA	80-99	P=O	34
	IA-90 TGC ACG ACA CTC ATA CTA AC	90-109	P=S	35
15	IA-100 TCC TGG AGG CTG CAC GAC AC	100-119	P=O/2', -OMe	36
	IA-106 GGG GGG TCC TGG AGG CTG CA	106-125	P=O/2', -OMe	39
	IA-108 AGG GGG GGT CCT GGA GGC TG	108-127	P=O/2', -OMe	40
	IA-110 GGA GAG GGG GTC CTG GAG GC	110-129	P=O/2', -OMe	41
	IA-112 CGG TCT CCC GGG GGG TCC TGG AG	112-131	P=O/2', -OMe	44
20	IA-120 GGC CCA CTA TGG CTC TCC CG	120-139	P=S	48
	IA-130 AGA CCA CTA TGG CTC TCC CG	130-149	P=S	49
	IA-140 CCG GTT CCG CAG ACC ACT AT	140-159	P=S	50
	IA-150 GGT GTA CTC ACC GGT TCC GC	150-169	P=O	51
	IA-160 TGG CAA TTC CGG TGT ACT CA	160-179	P=O/2', -OMe	52
25	IA-170 CCG GTC GTC CTG GCA ATT CC	170-189	P=S	53
	IA-180 AAG AAA GGA CCC GGT CGT CC	180-199	P=O/2', -OMe	54
	IA-190 GGG TTG ATC CAA GAA AGG AC	190-209	P=S	55
	IA-200 GGC ATT GAG CGG GTT GAT CC	200-219	P=S	56
	IA-210 CAA ATC TCC AGG CAT TGA GC	210-229	P=O/2', -OMe	57
	IA-220 GGG GCA CGC CCA AAT CTC CA	220-239	P=S	58
30	IA-230 CAG TCT CGC GGG GGC ACG CC	230-249	P=S	59
	IA-240 ACT CGG CTA GCA GTC TCG CG	240-259	P=O/2', -OMe	60
	IA-250 ACC CAA CAC TAC TCG GCT AG	250-269	P=S	61

IA-260	GCC TTT CGC GAC CCA ACA CT	260-279	P=S	P=O	P=O/2'-OMe	P=O/2'-OPro	62
IA-265	CAA GGC CTT TCG TCG AA	265-284	P=S		P=O/2'-OMe		92
IA-270	GTA CCA CAA GGC CTT TCG CG	270-289	P=S				63
IA-280	CTA TCA GGC AGT ACC ACA AG	280-299	P=S		P=O/2'-OMe		64
IA-290	CGC AAG CAC CCT ATC AGG CA	290-309	P=S				65
IA-300	CCG GGG CAC TCG CAA GCA CC	300-319	P=S	P=O	P=O/2'-OMe	P=O/2'-OPro	66
IA-310	ACG AGA CCT CCC GGG GCA CT	310-329	P=S				67
IA-320	TGC ACG GTC TAC GAG ACC TC	320-339	P=S		P=O/2'-OMe		68
IA-322	TGG TGC ACG GTC TAC GAG AC	322-341					69
IA-325	CAT GGT GCA CGG TCT ACG AG	325-344	P=S		P=O/2'-OMe	P=O/2'-OPro	93
IA-330	GTG CTC ATG GTG CAC GGT CT	330-349	P=S				73
IA-340	TTT AGG ATT CGT CAT GG	340-359	P=S		P=O/2'-OMe	P=O/2'-OPro	78
IA-350	TTC TTT GAG GTT TAG GAT TC	350-369	P=S				86
IA-360	CGT TTG GTT TTT CTT TGA GG	360-379	P=S	P=O	P=O/2'-OMe	P=O/2'-OPro	91
IA-364	GTT ACG TTT GGT TTT TCT TT	364-383	P=S		P=O/2'-OMe		94
IA-368	TGG TGT TAC GTT TGG TTT TT	368-387	P=S		P=O/2'-OMe		95
IA-371	GGT TGG TGT TAC GTT TGG TT	371-390	P=S		P=O/2'-OMe		96

P=S: phosphorothioate; P=O: phosphodiester; 2'-O-Me: 2'-O-methyl; 2'-O-Pro: 2'-O-propyl

- 36 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Kevin P. Anderson

(ii) TITLE OF INVENTION: Compositions And Methods For Treatment
Of Hepatitis C Virus-Associated Diseases

(iii) NUMBER OF SEQUENCES: 24

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Woodcock Washburn

Kurtz Mackiewicz & Norris

(B) STREET: One Liberty Place - 46th Floor

(C) CITY: Philadelphia

(D) STATE: PA

(E) COUNTRY: USA

(F) ZIP: 19103

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE

(B) COMPUTER: IBM PS/2

(C) OPERATING SYSTEM: PC-DOS

(D) SOFTWARE: WORDPERFECT 5.1

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: n/a

(B) FILING DATE: Herewith

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Jane Massey Licata

- 37 -

(B) REGISTRATION NUMBER: 32,257.

(C) REFERENCE/DOCKET NUMBER: ISIS-0486

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (215) 568-3100

(B) TELEFAX: (215) 568-3439

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

ATGGTGGAGT GTCGCCCCGT C (21)

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GGAGTGATCT ATGGTGGAGT G (21)

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

- 38 -

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GATTCGTGCT CATGGTGCAC G (21)

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TCCAGGCATT GAGCGGGTTG A (21)

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TGGCCTGGAG TGTTTATCTC C (21)

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

- 39 -

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGGGTAGGCA TCTACCTGCT C (21)

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CGCCCCCATC AGGGGGCTGG C (21)

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

TTCATGGTGG AGTGTGCCCC C (21)

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

- 40 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GTTCCTCACA GGGGAGTGAT T (21)

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TACTAACGCC ATGGCTAGAC G (21)

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

CTATGGCTCT CCCGGGAGGG G (21)

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

- 41 -

CCACTATGGC TCTCCCGGGA G (21)

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CGGTGTACTC ACCGGTTCCG C (21)

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CTGGCAATTC CGGTGTACTC A (21)

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GGGGCAGCC CAAATCTCCA G (21)

- 42 -

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CCTTTCGCGA CCCAACACTA C (21)

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CCCTATCAGG CAGTACCACA A (21)

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

CTCCCGGGGC ACTCGCAAGC A (21)

(2) INFORMATION FOR SEQ ID NO: 19:

- 43 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

CATGGTGCAC GGTCTACGAG A (21)

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

GTCCTGGAGG CTGCACGACA (20)

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

TTTAGGATTC GTGCTCATGG T (21)

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

- 44 -

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GAGTGGTTAG CCAATCTTC A (21)

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

TATTGGCCTG GAGTGGTTAG C (21)

(2) INFORMATION FOR SEQ ID NO: 24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 21
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

AGGGAATGGC CTATTGGCCT G (21)

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 686

- 45 -

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: No

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

GCCAGCCCCC GAUUGGGGGC GACACUCCAC CAUAGAUACAC UCCCCUGUGA
 GGAACUACUG UCUUCACGCA GAAAGCGUCU AGCCAUGGCG UUAGUAUGAG UGUCGUGCAG
 CCUCCAGGAC CCCCCUCCC GGGAGAGCCA UAGUGGUCUG CGGAACCGGU GAGUACACCG
 GAAUUGCCAG GACGACCGGG UCCUUUCUUG GAUCAACCCG CTCAAUGCCU GGAGAUUUGG
 GCGUGCCCCC GCGAGACUGC UAGCCGAGUA GUGUUGGGUC GCGAAAGGCC UUGUGGUACU
 GCCUGAUAGG GUGCUUGCGA GUGCCCCGGG AGGUCUCGUA GACCGUGCAC CAUGAGCACG
 AAUCCUAAAC CUCAAAGAAA AACCAAACGU AACACCAACC GCCGCCACA GGAGGUCAAG
 UUCCCGGGCG GUGGUCAGAU CGUUGGUGGA GUUUACCUGU UGCCGCGCAG GGGCCCCAGG
 UUGGGUGUGC GCGCGAUCAG GAAGACUCC GAGCGGUCGC AACCCCGUGG AAGGCGACAG
 CCUAUCCCCA AGGCUCGCCG GCCCGAGGGC AGGGCCUGGG CUCAGCCCGG GUAUCCUUGG
 CCCUCUAUG GCAAUGAGGG CAUGGGGUGG GCAGGAUGGC UCCUGUCACC CCGCGGCUCC
 CGGCCUAGUU GGGGCCCCAC GGACCCCCGG CGUAGG (686)

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

GCCCCGAATC GGGGGCTGGC (20)

(2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:

- 46 -

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

TGGAGTGTCTG CCCCCAATCG (20)

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

TGATCTATGG TGGAGTGTCTG (20)

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

CACAGGGGAG TGATCTATGG (20)

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20

- 47 -

- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

AGTAGTTCCT CACAGGGGAG (20)

(2) INFORMATION FOR SEQ ID NO: 31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

GCGTGAAGAC AGTAGTTCCT (20)

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

GACGCTTTCT GCGTGAAGAC (20)

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic

- 48 -

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

GCCATGGCTA GACGCTTTCT (20)

(2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

TCATACTAAC GCCATGGCTA (20)

(2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

TGCACGACAC TCATACTAAC (20)

(2) INFORMATION FOR SEQ ID NO: 36:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

- 49 -

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

TCCTGGAGGC TGCACGACAC (20)

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

GGTCCTGGAG GCTGCACGAC (20)

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

GGGGTCCTGG AGGCTGCACG (20)

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

- 50 -

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

GGGGGGTCCT GGAGGCTGCA (20)

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

AGGGGGGGTC CTGGAGGCTG (20)

(2) INFORMATION FOR SEQ ID NO: 41:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

GGAGGGGGGG TCCTGGAGGC (20)

(2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

- 51 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

GGAGGGGGGG iCCTGGAGGC (20)

(2) INFORMATION FOR SEQ ID NO: 43:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

GGAGGGGGGG GCCTGGAGGC (20)

(2) INFORMATION FOR SEQ ID NO: 44:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

CGGGAGGGGG GGTCTGGAG (20)

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

- 52 -

CCCGGGAGGG GGGGTCCTGG (20)

(2) INFORMATION FOR SEQ ID NO: 46:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

CTCCCGGGAG GGGGGGTCCT (20)

2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

CTCTCCCGGG AGGGGGGGTC (20)

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

GGCTCTCCCG GGAGGGGGGG (20)

- 53 -

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

AGACCACTAT GGCTCTCCCG (20)

(2) INFORMATION FOR SEQ ID NO: 50:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

CCGGTTCCGC AGACCACTAT (20)

(2) INFORMATION FOR SEQ ID NO: 51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

GGTGACTCA CCGGTTCCGC (20)

(2) INFORMATION FOR SEQ ID NO: 52:

- 54 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

TGGCAATTCC GGTGTACTCA (20)

(2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

CCGGTCGTCC TGGCAATTCC (20)

(2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

AAGAAAGGAC CCGGTCGTCC (20)

(2) INFORMATION FOR SEQ ID NO: 55:

(i) SEQUENCE CHARACTERISTICS:

- 55 -

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55:

GGGTTGATCC AAGAAAGGAC (20)

(2) INFORMATION FOR SEQ ID NO: 56:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56:

GGCATTGAGC GGGTTGATCC (20)

(2) INFORMATION FOR SEQ ID NO: 57:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57:

CAAATCTCCA GGCATTGAGC (20)

(2) INFORMATION FOR SEQ ID NO: 58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20

- 56 -

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58:

GGGGCACGCC CAAATCTCCA (20)

(2) INFORMATION FOR SEQ ID NO: 59:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59:

CAGTCTCGCG GGGGCACGCC (20)

(2) INFORMATION FOR SEQ ID NO: 60:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60:

ACTCGGCTAG CAGTCTCGCG (20)

(2) INFORMATION FOR SEQ ID NO: 61:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

- 57 -

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61:

ACCCAACACT ACTCGGCTAG (20)

(2) INFORMATION FOR SEQ ID NO: 62:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62:

GCCTTTCGCG ACCCAACACT (20)

(2) INFORMATION FOR SEQ ID NO: 63:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63:

GTACCACAAG GCCTTTCGCG (20)

(2) INFORMATION FOR SEQ ID NO: 64:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

- 58 -

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64:

CTATCAGGCA GTACCACAAG (20)

(2) INFORMATION FOR SEQ ID NO: 65:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65:

CGCAAGCACC CTATCAGGCA (20)

(2) INFORMATION FOR SEQ ID NO: 66:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66:

CCGGGGCACT CGCAAGCACC (20)

(2) INFORMATION FOR SEQ ID NO: 67:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

- 59 -

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67:

ACGAGACCTC CCGGGGCACT (20)

(2) INFORMATION FOR SEQ ID NO: 68:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68:

TGCACGGTCT ACGAGACCTC (20)

(2) INFORMATION FOR SEQ ID NO: 69:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69:

GGTGACGGT CTACGAGACC (20)

(2) INFORMATION FOR SEQ ID NO: 70:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

- 60 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70:

ATGGTGCACG GTCTACGAGA (20)

(2) INFORMATION FOR SEQ ID NO: 71:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71:

TCATGGTGCA CGGTCTACGA (20)

(2) INFORMATION FOR SEQ ID NO: 72:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72:

GCTCATGGTG CACGGTCTAC (20)

(2) INFORMATION FOR SEQ ID NO: 73:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73:

- 61 -

GTGCTCATGG TGCACGGTCT (20)

(2) INFORMATION FOR SEQ ID NO: 74:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74:

TCGTGCTCAT GGTGCACGGT (20)

(2) INFORMATION FOR SEQ ID NO: 75:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75:

ATTCGTGCTC ATGGTGCACG (20)

(2) INFORMATION FOR SEQ ID NO: 76:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76:

GGATTCGTGC TCATGGTGCA (20)

- 62 -

(2) INFORMATION FOR SEQ ID NO: 77:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77:

TAGGATTCGT GCTCATGGTG (20)

(2) INFORMATION FOR SEQ ID NO: 78:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78:

TTTAGGATTC GTGCTCATGG (20)

(2) INFORMATION FOR SEQ ID NO: 79:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79:

GGTTTAGGAT TCGTGCTCAT (20)

(2) INFORMATION FOR SEQ ID NO: 80:

- 63 -

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80:

GAGGTTTAGG ATTCGTGCTC (20)

(2) INFORMATION FOR SEQ ID NO: 81:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81:

GAGGTTTAGG ATTtGTGCTC (20)

(2) INFORMATION FOR SEQ ID NO: 82:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82:

GiGGTTTiGG ATTtGTGCTC (20)

(2) INFORMATION FOR SEQ ID NO: 83:

(i) SEQUENCE CHARACTERISTICS:

- 64 -

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83:

GiGGTTTiGG AiiiGTGCTC (20)

(2) INFORMATION FOR SEQ ID NO: 84:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84:

TTGAGGTTTA GGATTCGTGC (20)

(2) INFORMATION FOR SEQ ID NO: 85:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20
- (B) TYPE: Nucleic
- (C) STRANDEDNESS: Single
- (D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85:

CTTTGAGGTT TAGGATTCGT (20)

(2) INFORMATION FOR SEQ ID NO: 86:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20

- 65 -

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86:

TTCTTTGAGG TTTAGGATTC (20)

(2) INFORMATION FOR SEQ ID NO: 87:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87:

TTTTCTTTGA GGTTTAGGAT (20)

(2) INFORMATION FOR SEQ ID NO: 88:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88:

GTTTTTCTTT GAGGTTTAGG (20)

(2) INFORMATION FOR SEQ ID NO: 89:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

- 66 -

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89:

TGGTTTTTCT TTGAGGTTTA (20)

(2) INFORMATION FOR SEQ ID NO: 90:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90:

TTTGGTTTTT CTTTGAGGTT (20)

(2) INFORMATION FOR SEQ ID NO: 91:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91:

CGTTTGTTTT TTCTTTGAGG (20)

(2) INFORMATION FOR SEQ ID NO: 92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

- 67 -

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92:

CAAGGCCTTT CGCGACCCAA (20)

(2) INFORMATION FOR SEQ ID NO: 93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93:

CATGGTGCAC GGTCTACGAG (20)

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

GTTACGTTTG GTTTTTCTTT (20)

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

- 68 -

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

TGGTGTTACG TTTGGTTTTT (20)

(2) INFORMATION FOR SEQ ID NO: 96:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: Nucleic

(C) STRANDEDNESS: Single

(D) TOPOLOGY: Linear

(iv) ANTI-SENSE: Yes

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96:

GGTTGGTGTT ACGTTTGGTT (20)

- 69 -

CLAIMS

1. An oligonucleotide which has a nucleotide sequence complementary to at least a portion of HCV genomic or messenger RNA, said oligonucleotide being hybridizable to 5 said RNA.

2. An oligonucleotide of claim 1 wherein said RNA comprises the 5' end hairpin loop, 5' end 6-base-pair repeat, 5' end untranslated region, polyprotein translation initiation codon, ORF 3 translation initiation codon, 3'-untranslated 10 region, 3' end palindrome region, R2 sequence or 3' end hairpin loop of an HCV RNA.

3. An oligonucleotide of claim 1 in a pharmaceutically acceptable carrier.

4. An oligonucleotide of claim 1 comprising from 15 5 to 50 nucleotides.

5. An oligonucleotide of claim 4 comprising one of the sequences identified in Table 1.

6. A method for modulating the activity of Hepatitis C virus comprising contacting the virus or cells 20 infected with the virus with an oligonucleotide complementary to at least a portion of an HCV RNA, said oligonucleotide being hybridizable to said RNA.

7. The method of claim 6 wherein said RNA comprises the 5' end hairpin loop, 5' end 6-base-pair repeat, 25 5' end untranslated region, polyprotein translation initiation codon, ORF 3 translation initiation codon, 3'-untranslated region, 3' end palindrome region, R2 sequence or 3' end hairpin loop of an HCV RNA.

- 70 -

8. The method of claim 6 wherein said oligonucleotide is in a pharmaceutically acceptable carrier.

9. The method of claim 6 wherein said oligonucleotide comprises from 5 to 50 nucleotides.

5 10. The method of claim 9 wherein said oligonucleotide comprises one of the sequences identified in Table 1.

11. A method for treating an HCV-associated disease comprising contacting an animal suspected of having an HCV-
10 associated disease with a therapeutically effective amount of an oligonucleotide which has a nucleotide sequence complementary to at least a portion of HCV RNA, said oligonucleotide being hybridizable to said RNA.

12. The method of claim 11 wherein said RNA
15 comprises the 5' end hairpin loop, 5' end 6-base-pair repeat, 5' end untranslated region, polyprotein translation initiation codon, ORF 3 translation initiation codon, 3'-untranslated region, 3' end palindrome region, R2 sequence or 3' end hairpin loop of an HCV RNA.

20 13. The method of claim 11 wherein the oligonucleotide is in a pharmaceutically acceptable carrier.

14. The method of claim 11 wherein said oligonucleotide comprises from 5 to 50 nucleotides.

15. The method of claim 12 wherein said
25 oligonucleotide comprises one of the sequences identified in Table 1.

16. An oligonucleotide of claim 1, which is hybridizable with the following nucleotide sequence (A) or a nucleotide sequence which is highly homologous to said

- 71 -

nucleotide sequence (A) which are present at 5'-untranslated region in the nucleotide sequence of Hepatitis C virus genome:

(A) GCCUCCAGGACCCC.

17. An oligonucleotide of claim 16, wherein the 5 oligonucleotide has at least 14 nucleic acid base units.

18. An oligonucleotide of claim 16, wherein the oligonucleotide contains at least an antisense nucleotide sequence to said nucleotide sequence (A).

19. An oligonucleotide of claim 18, wherein the 10 oligonucleotide is a nucleic acid having 20 base units which contains an antisense nucleotide sequence to said nucleotide sequence (A).

20. An oligonucleotide of claim 18, wherein the oligonucleotide contains at least an antisense nucleotide 15 sequence to said nucleotide sequence (A) and further contains an antisense oligonucleotide which is complementary to a nucleic acid having 14 to 26 continuous nucleotide sequence in the following nucleotide sequence (B):

(B) CGUGCAGCCUCCAGGACCCCCCUCC.

20 21. An oligonucleotide of claim 16, wherein the oligonucleotide is a chemically modified compound.

22. An oligonucleotide of claim 21, wherein the oligonucleotide is a phosphorothioate compound.

23. An oligonucleotide of claim 1, which is 25 hybridable with a nucleotide sequence of the nucleotide number 352 to 355 (AUCC) of HCV DNA or neighbor thereof.

24. An agent for the treatment of Hepatitis C virus-associated diseases, which comprises as an active ingredient an oligonucleotide as set forth in any one of

- 72 -

claims 1-5 and 16-23.

25. Use of the oligonucleotide as set forth in any one of claims 1-5 and 16-23 for treating an HCV-associated disease.

5 26. The oligonucleotide of claim 2 wherein said RNA comprises at least a portion of the loop B region or the loop C region of the 5'-end untranslated region of an HCV RNA.

27. The oligonucleotide of claim 26 wherein said RNA comprises nucleotides 104-129 of the 5'-end untranslated
10 region of an HCV RNA.

28. The oligonucleotide of claim 26 comprising SEQ ID NO: 33, SEQ ID NO:41, SEQ ID NO: 20, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44 or SEQ ID NO:45.

15 29. The oligonucleotide of claim 2 wherein said RNA comprises at least a portion of the loop F region of the 5'-end untranslated region of an HCV RNA.

30. The oligonucleotide of claim 29 comprising SEQ ID NO: 62.

20 31. The oligonucleotide of claim 2 wherein said RNA comprises at least a portion of the polyprotein translation initiation codon of an HCV RNA.

32. The oligonucleotide of claim 31 comprising SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:72, SEQ ID NO:76, SEQ ID
25 NO:77, SEQ ID NO:78, SEQ ID NO:79 or SEQ ID NO:80.

33. An oligonucleotide of claim 1 wherein said RNA comprises at least a portion of the core protein coding region

- 73 -

of an HCV RNA.

34. An oligonucleotide of claim 33 comprising the sequence GGAT.

35. An oligonucleotide of claim 33 comprising SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90 or SEQ ID NO:91.

36. An oligonucleotide of claim 1 which comprises at least one phosphorothioate intersugar linkage.

37. An oligonucleotide of claim 1 which comprises an -O-alkyl modification at the 2'-position of at least one sugar moiety.

38. An oligonucleotide of claim 37 wherein the -O-alkyl modification is an -O-methyl or -O-propyl modification.

39. An oligonucleotide of claim 1 having a universal base at a position which is complementary to a nucleotide in the HCV RNA which is variable among strains of HCV.

40. An oligonucleotide of claim 39 wherein the universal base is inosine.

- 74 -

41. The method of claim 7 wherein said RNA comprises at least a portion of the loop B region or the loop C region of the 5'-end untranslated region of an HCV RNA.

42. The method of claim 41 wherein said RNA comprises nucleotides 104-129 of the 5'-end untranslated region of an HCV RNA.

43. The method of claim 41 wherein said oligonucleotide comprises SEQ ID NO: 33, SEQ ID NO:41, SEQ ID NO: 20, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO: 10 42, SEQ ID NO:44 or SEQ ID NO:45.

44. The method of claim 7 wherein said RNA comprises at least a portion of the loop F region of the 5'-end untranslated region of an HCV RNA.

45. The method of claim 44 wherein said 15 oligonucleotide comprises SEQ ID NO: 62.

46. The method of claim 7 wherein said RNA comprises at least a portion of the polyprotein translation initiation codon of an HCV RNA.

47. The method of claim 46 wherein said 20 oligonucleotide comprises SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79 or SEQ ID NO:80.

48. The method of claim 6 wherein said RNA comprises at least a portion of the core protein coding region 25 of an HCV RNA.

49. The method of claim 48 wherein said oligonucleotide comprises the sequence GGAT.

- 75 -

50. The method of claim 48 wherein said oligonucleotide comprises SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90 or SEQ ID NO:91.

5 51. The method of claim 6 wherein said oligonucleotide comprises at least one phosphorothioate intersugar linkage.

52. The method of claim 6 wherein said oligonucleotide comprises an -O-alkyl modification at the 2'-
10 position of at least one sugar moiety.

53. The method of claim 52 wherein the -O-alkyl modification is an -O-methyl or -O-propyl modification.

54. The method of claim 6 wherein said oligonucleotide has a universal base at a position which is
15 complementary to a nucleotide in the HCV RNA which is variable among strains of HCV.

55. The method of claim 54 wherein the universal base is inosine.

56. The method of claim 12 wherein said RNA
20 comprises at least a portion of the loop B region or the loop C region of the 5'-end untranslated region of an HCV RNA.

57. The method of claim 56 wherein said RNA comprises nucleotides 104-129 of the 5'-end untranslated region of an HCV RNA.

25 58. The method of claim 56 wherein said oligonucleotide comprises SEQ ID NO: 33, SEQ ID NO:41, SEQ ID NO: 20, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO: 42, SEQ ID NO:44 or SEQ ID NO:45.

- 76 -

59. The method of claim 12 wherein said RNA comprises at least a portion of the loop F region of the 5'-end untranslated region of an HCV RNA.

60. The method of claim 59 wherein said 5 oligonucleotide comprises SEQ ID NO: 62.

61. The method of claim 12 wherein said RNA comprises at least a portion of the polyprotein translation initiation codon of an HCV RNA.

62. The method of claim 61 wherein said 10 oligonucleotide comprises SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:79 or SEQ ID NO:80.

63. The method of claim 11 wherein said RNA comprises at least a portion of the core protein coding region 15 of an HCV RNA.

64. The method of claim 63 wherein said oligonucleotide comprises the sequence GGAT.

65. The method of claim 63 wherein said oligonucleotide comprises SEQ ID NO:84, SEQ ID NO:85, SEQ ID 20 NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90 or SEQ ID NO:91.

66. The method of claim 11 wherein said oligonucleotide comprises at least one phosphorothioate intersugar linkage.

25 67. The method of claim 11 wherein said oligonucleotide comprises an -O-alkyl modification at the 2'-position of at least one sugar moiety.

- 77 -

68. The method of claim 67 wherein the -O-alkyl modification is an -O-methyl or -O-propyl modification.


69. The method of claim 11 wherein said oligonucleotide has a universal base at a position which is 5 complementary to a nucleotide in the HCV RNA which is variable among strains of HCV.

70. The method of claim 69 wherein the universal base is inosine.

Figure 1

GCCAGCCCCGAUUGGGGGCGACAUCCACCAUAGAUCACUCCCCUGUGAGGAACUACUGUCUACGCAG
AAAGCGUCUAGCCAUGGCGUAGUAUGAGUGUCGUGCAGCCUCCAGGACCCCCCUCCCGGAGAGCCAUA
GUGGUCUGCGGAACCGGUGAGUACACCGAAUUGCCAGGACGACCGGGUCCUUCUUGGAUCAACCGCTC
AAUGCCUGGAGAUUUGGGCGUGCCCCCGGAGACUGCUAGCCGAGUAGUGUUGGGUCGCGAAAGGCCUUGU
GGUACUGCCUGAUAGGGUGCUUGCGAGUGCCCCGGGAGGUCUGUAGACCGUGCACCAUGAGCAGGAAUCC
UAAACCUCAAAGAAAAACCAAACGUAACACCAACCGCGCCACAGGAGGUCAAGUUCCTGGGCGGUGGUC
AGAUCGUUGGUGGAGUUUACCUGUUGCCGCGCAGGGGCCCCAGGUUGGGUGUGCGCGGAUCAGGAAGACU
UCCGAGCGGUCGCAACCCCGUGGAAGGCGACAGCCUAUCCCCAAGGUCGCGCGGCCGAGGGCAGGGCCUG
GGCUCAGCCCGGUAUCCUUGGCCCCUCUAUGGCAAUGAGGGCAUGGGGUGGGCAGGAUGGCUCUGUCAC
CCCGCGGCUCCCGGCCUAGUUGGGGCCCCACGGACCCCCGGCGUAGG



Figure 2



Inhibition of Core protein translation in the presence of antisense oligonucleotide

Figure 3

2'-o-methyl modified P=O oligos (ISIS oligos)




P=O oligos (ISIS oligos)

Inhibitory activity of 2'-o-methyl modified oligos and phosphodiester oligos from ISIS by in vitro core translation.
mRNA:oligos (1:5, molar ratio)

Figure 4

Influence of oligo. sequence and RNA length on in vitro translation

P=O



RNA709 : from Cla I-digested pGEM NCE1 plasmid
RNA1375 : from Bam HI-digested pGEM NCE1 plasmid

Figure 5

Screening of the 2'-O-Methyl /P=O antisense oligonucleotides by in vitro translation assay





Figure 6

Inhibition of HCV translation by the 2'-O-Methyl/P=O antisense oligonucleotides
around C-loop and AUG codon



7/9

Figure 7




Figure 8

Screening of the P=S oligos. by in vitro translation assay after treatment with RNase H





Figure 9

Inhibitory activities of 2'OPro/P=O and 2'OMe/P=O oligos.



INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 93/01293

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C12Q1/70 C12N15/11 C07K15/00 C07H21/00 //G01N33/576

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12Q C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,92 12992 (JAMES N. GAMBLE INSTITUTE OF MEDICAL RESEARCH) 6 August 1992 see page 64 - page 71 see page 155 - page 186; claims 70-92,107,108 ---	1-22, 24-33, 35-70
X	WO,A,92 02642 (CHIRON CORP) 20 February 1992 see the whole document especially see page 22, line 9 - page 23, line 8; examples --- -/--	1-5

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

7 February 1994

Date of mailing of the international search report

21.02.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Molina Galan, E

INTERNATIONAL SEARCH REPORT

Inter: nal Application No

PCT/JP 93/01293

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP,A,0 518 313 (MITSUBISHI) 16 December 1992 see the whole document especially see claims 33-38; examples ---	1-70
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 88 , March 1991 , WASHINGTON US pages 1711 - 1715 HAN ET AL. 'Characterization of the terminal regions of HCV RNA' cited in the application see the whole document ----	1-4
X	JOURNAL OF CLINICAL INVESTIGATIONS. vol. 89 , June 1992 , NEW YORK US pages 2040 - 2045 HU ET AL. 'Direct detection of circulating HCV RNA using probes from the 5' UTR' introduction -----	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 93/01293

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9212992	06-08-92	AU-A- 1459792 EP-A- 0571554	27-08-92 01-12-93
WO-A-9202642	20-02-92	AU-A- 8509991 CA-A- 2089080 EP-A- 0543924	02-03-92 11-02-92 02-06-93
EP-A-0518313	16-12-92	NONE	